325 related articles for article (PubMed ID: 36001104)
21. Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.
Miyoshi H; Matsuhisa M; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
Diabetes Ther; 2023 Apr; 14(4):671-689. PubMed ID: 36809494
[TBL] [Abstract][Full Text] [Related]
22. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.
Giorgino F; Caruso I; Napoli R
Diabetes Res Clin Pract; 2020 Dec; 170():108478. PubMed ID: 33002548
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.
Visolyi GÁ; Domján BA; Svébis MM; Péterfi A; Lovász BD; Mészáros S; Horváth VJ; Tabák ÁG
Can J Diabetes; 2023 Jun; 47(4):368-377. PubMed ID: 36963632
[TBL] [Abstract][Full Text] [Related]
24. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.
Kim K; Unni S; McAdam-Marx C; Thomas SM; Sterling KL; Olsen CJ; Johnstone B; Mitchell M; Brixner D
J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811
[TBL] [Abstract][Full Text] [Related]
25. Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.
Lin J; Lingohr-Smith M; Fan T
Clinicoecon Outcomes Res; 2017; 9():19-29. PubMed ID: 28053550
[TBL] [Abstract][Full Text] [Related]
26. EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.
Mora PF; Chao J; Saremi A; Dex TA; Roberts M; Umpierrez GE
Endocr Pract; 2019 Nov; 25(11):1091-1100. PubMed ID: 31241362
[No Abstract] [Full Text] [Related]
27. Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
Risovic I; Dumanovic MS; Bojic M; Djekic D
BMC Endocr Disord; 2023 Feb; 23(1):28. PubMed ID: 36726134
[TBL] [Abstract][Full Text] [Related]
28. Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study.
Pantalone KM; Heller C; Lajara R; Lew E; Li X; Dex T; Kilpatrick CR
Diabetes Spectr; 2023; 36(3):253-263. PubMed ID: 37583559
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA.
Singhal M; Tan H; Coleman CI; Han M; Nguyen C; Ingham M
BMJ Open Diabetes Res Care; 2019; 7(1):e000704. PubMed ID: 31798890
[TBL] [Abstract][Full Text] [Related]
30. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.
Rayner CK; Wu T; Aroda VR; Whittington C; Kanters S; Guyot P; Shaunik A; Horowitz M
Diabetes Obes Metab; 2021 Jan; 23(1):136-146. PubMed ID: 32991041
[TBL] [Abstract][Full Text] [Related]
31. Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
Terauchi Y; Yabe D; Kaneto H; Amano A; Baxter M; Watanabe D; Watada H; Inagaki N
Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():35-47. PubMed ID: 33404200
[TBL] [Abstract][Full Text] [Related]
32. Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.
Schmider W; Belder R; Lee M; Niemoeller E; Souhami E; Frias JP
Curr Med Res Opin; 2019 Jun; 35(6):1081-1089. PubMed ID: 30550345
[TBL] [Abstract][Full Text] [Related]
33. Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study.
Blonde L; Rosenstock J; Frias J; Birkenfeld AL; Niemoeller E; Souhami E; Ji C; Del Prato S; Aroda VR
Diabetes Care; 2021 Mar; 44(3):774-780. PubMed ID: 33468520
[TBL] [Abstract][Full Text] [Related]
34. Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.
Guja C; Giorgino F; Blonde L; Ali A; Prázný M; Meier JJ; Souhami E; Lubwama R; Ji C; Rosenstock J
Diabetes Ther; 2022 Jan; 13(1):205-215. PubMed ID: 34894329
[TBL] [Abstract][Full Text] [Related]
35. Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
Davies MJ; Leiter LA; Guerci B; Grunberger G; Ampudia-Blasco FJ; Yu C; Stager W; Niemoeller E; Souhami E; Rosenstock J
Diabetes Obes Metab; 2017 Dec; 19(12):1798-1804. PubMed ID: 28432746
[TBL] [Abstract][Full Text] [Related]
36. Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.
Bailey TS; Gill J; Jones S M; Shenoy L; Nicholls C; Westerbacka J
Diabetes Obes Metab; 2022 Aug; 24(8):1617-1622. PubMed ID: 35491520
[TBL] [Abstract][Full Text] [Related]
37. Real-world effectiveness and safety of insulin glargine 100 U/mL plus lixisenatide in adults with type 2 diabetes: An international, multicentre, 12-month, prospective observational study.
Malik RA; Hwu CM; Jammah AA; Arteaga-Díaz JM; Djaballah K; Pilorget V; Alvarez A; Vera C; Vikulova O
Diabetes Obes Metab; 2024 Jul; 26(7):2811-2819. PubMed ID: 38637981
[TBL] [Abstract][Full Text] [Related]
38. Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).
Bala C; Cerghizan A; Mihai BM; Moise M; Guja C
BMJ Open; 2022 May; 12(5):e060852. PubMed ID: 35623748
[TBL] [Abstract][Full Text] [Related]
39. Personalized Care and the Role of Insulin as a Vehicle to Optimizing Treatments in Diabetes Care.
Bieszk N; Grabner M; Wei W; Barron J; Quimbo R; Yan T; Biel B; Chu JW
J Manag Care Spec Pharm; 2017 Nov; 23(11):1160-1168. PubMed ID: 29083969
[TBL] [Abstract][Full Text] [Related]
40. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
